DUBLIN, October 27, 2017 /PRNewswire/ --
The "Cell Line Development Services Global Market - Forecast to 2025" report has been added to Research and Markets' offering.
The cell line development service market is expected to grow at double digit CAGR to reach $1,214.7 million by 2025
Cell lines are one the major tools used in research for studying the normal physiology and biochemistry of cells, the effects of drugs and toxic compounds on the cells, drug screening and development and large scale manufacturing of biological compounds. Cell culture is the process by which cells are grown under controlled conditions derived from microbial or animal cells. Cell lines are subculture of primary culture also known as sub-clone. Cell lines derived from primary cultures have a limited life span, after subsequent cultures, cells with the highest growth capacity dominate which are selected for further cell development. Primary cells are cells that are cultured directly from a subject and have a limited lifespan. An immortalized cell line can proliferate indefinitely either through random mutation or deliberate modification which are useful especially for production of therapeutics.
Increasing demand for biologics and biosimilars, growing incidence rate of oncology and immunological disorder and growth in research activities related to the diseases are driving the market. Technological improvements in development, manufacturing, screening technologies and assays are giving immense growth opportunity for the market. However, complexities in development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market. Furthermore, stringent and complex regulations and high cost and technical requirement to adhere with accreditations such as GMP are posing threat to the industry.
Cell lines are essential for a wide range of applications including gene function studies, drug discovery assays, the production of biotherapeutics and diagnostics. The application for cell lines includes research, bioproduction and diagnostics. Among research, cell lines are used for studying disease, screening, cell-based assays are used during discovery phase and preclinical development. Cell lines are used to produce a wide range of biotherapeutics including vaccine, recombinant proteins that include peptides, cytokines, hormones and clotting factors, enzymes and monoclonal antibodies.
Key Topics Covered:
1 Executive Summary
2 Market Dynamics
2.1 Market Dynamics
2.1.1 Drivers and Opportunities
2.1.1.1 Growing Incidence Rates of Oncology and Immunological Disorders and Increasing R&D Activities Related to the Diseases.
2.1.1.2 Increasing Demand for Biologics and Biosimilars
2.1.1.3 Advanced Technologies for Screening, Cell Line Engineering and Bioprocessing
2.1.1.4 Increasing Number of Cros in Apac Regions
2.1.2 Restraints and Threats
2.1.2.1 Complexities in Development of Stable Cell Lines
2.1.2.2 High Risk of Contamination Due to Complex Purification Method
2.1.2.3 Stringent and Complex Regulations for Biologics in North America and Europe
2.1.2.4 High Cost and Technical Requirements to Obtain Gmp Certifications
2.2 Cell Line Development
2.3 Host Cell Lines
3 Cell Line Development Services Market, by Expression System
3.1 Microbial Expression Systems
3.2 Mammalian Expression System
3.3 Others
4 Cell Line Development Services, by Cell Type
4.1 Cho
4.2 Murine/Mouse Myeloma
4.3 Baby Hamster Kidney (Bhk) Cells
4.4 Hybridoma
4.5 Human Embryonic Kidney (Hek) Cells
4.6 Human Embryonic Retinal Cells (Per.C6)
4.7 Others
5 Cell Line Development Services, by Application
5.1 Research
5.2 Bioproduction
5.3 Diagnostics
6 Cell Line Development Technological Advancements
7 Key Developments
8 Market Share Analysis
9 Company Profiles
- Abeomics
- Abgenex
- Abmgood
- Abzena
- Acro Biosystems
- Amgen
- Amplycell
- Applied Stem Cell
- Aragen (Gvk)
- Atcc
- Atum
- Boehringer Ingelheim
- Bps Bioscience
- C & M Biolabs
- Catalent
- Cellomics Technology
- Celonic
- Charles River
- Chromos Molecular Systems
- Cobra Biologics
- Cook Pharmica
- Creative Biolabs
- Crown Bioscience
- Crucell
- Cytovance Biologics
- Eurofins
- Evotec
- Exonbio
- Fujifilm Diosynth Biotechnologies
- Fusion Antibodies
- G&P Biosciences
- Gen Target
- Genscript
- Glycotope
- Goodwinbiotechnology
- Horizon Discovery
- Jhl Biotech
- Jsr Life Sciences
- Kbi Biopharma (Jsr)
- Lakepharma
- Lfb Biomanufacturing
- Lonza
- Mabplex
- Merck Kgaa
- Oxford Genetics
- Patheon
- Precision Antibody
- Probiogen
- Profacgen
- Rentschler Biotech
- Sartorius Stedim Biotech S.A.
- Selexis
- Sgi-Dna
- Sino Biological
- Speed Biosystem
- Sydlabs
- Syngene
- Tcg Lifesciences
- Texcell
- Trenzyme
- Uga Biopharma
- Wuxi Apptec
For more information about this report visit https://www.researchandmarkets.com/research/qqsfrp/cell_line
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article